Does Gender-Affirming Hormonal Treatment Affect 30-Year Cardiovascular Risk in Transgender Persons? A Two-Year Prospective European Study (ENIGI)

Cardiovascular (CV) implications of long-term gender affirming hormonal treatment (GAHT) in transgender individuals still remain largely unknown. To evaluate changes in the 30-year Framingham cardiovascular disease (CVD) risk in a large cohort of transgender individuals after the start of GAHT. In a...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of sexual medicine 2021-04, Vol.18 (4), p.821-829
Hauptverfasser:	Cocchetti, Carlotta, Castellini, Giovanni, Iacuaniello, Davide, Romani, Alessia, Maggi, Mario, Vignozzi, Linda, Schreiner, Thomas, den Heijer, Martin, T'Sjoen, Guy, Fisher, Alessandra Daphne
Format:	Artikel
Sprache:	eng
Schlagworte:	Cardiovascular Risk Gender Affirming Hormonal Treatment Lipid Profile
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!